CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Psilocybindrug
Likely dose
Psilocybin 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05399498
NCT05399498Phase 2Completed
CompareCT.gov

An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder

University of Chicago·interventional·Posted Jun 1, 2022·Updated Dec 23, 2025

In Brief

A Phase 2 clinical trial evaluating Psilocybin for Borderline Personality Disorder and Major Depressive Disorder. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBorderline Personality Disorder, Major Depressive Disorder
CountriesUnited States
CollaboratorsUsona Institute

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJun 1, 2022
Enrollment StartNov 1, 2023
Primary CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 4.1 years ago

Interventions

Psilocybindrug

Psilocybin 25mg capsule